Incyte (INCY) Gross Profit Growth (3y) (2015 - 2026)

Incyte (INCY) Gross Profit Growth (3y) (2015 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Profit Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 54.36%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 7.16%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 3.86%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 79.18%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Incyte 23.64 Bn 19.62 Bn 1.17 Bn 15.82%

Historic Data

Download Data
DateValue
Mar 31, 2026 15.82%
Dec 31, 2025 16.89%
Sep 30, 2025 18.12%
Jun 30, 2025 9.71%
Mar 31, 2025 12.36%
Dec 31, 2024 10.01%
Sep 30, 2024 10.81%
Jun 30, 2024 13.15%
Mar 31, 2024 12.52%
Dec 31, 2023 7.80%
Sep 30, 2023 13.57%
Jun 30, 2023 10.62%
Mar 31, 2023 11.58%
Dec 31, 2022 16.61%
Sep 30, 2022 13.80%
Jun 30, 2022 19.81%
Mar 31, 2022 13.27%
Dec 31, 2021 17.72%
Sep 30, 2021 22.08%
Jun 30, 2021 10.37%